References
- Tae K, Jin BJ, Ji YB, Jeong JH, Cho SH, Lee SH. The role of laryngopharyngeal reflux as a risk factor in laryngeal cancer: a preliminary report. Clin Exp Otorhinolaryngol 2011;4:101–4.
- Pogna EA, Clayton AL, Mahadevan LC. Signalling to chromatin through post-translational modifications of HMGN. Biochim Biophys Acta 2010;1799:93–100.
- Hillion J, Wood LJ, Mukherjee M, Bhattacharya R, Di Cello F, Kowalski J, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated large-cell lung cancer. Mol Cancer Res 2009;7:1803–12.
- Hristov AC, Cope L, Di Cello F, Reyes MD, Sinqh M, Hillion JA, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adeno-carcinoma. Mod Pathol 2010;23:98–104.
- Arpin M, Chirivino D, Naba A, Zwaenepoel I. Emerging role for ERM proteins in cell adhesion and migration. Cell Adh Migr 2011;5:199–206.
- Liau SS, Whang E. High mobility group A: a novel biomarker and therapeutic target in pancreatic adenocarcinoma. Surgeon 2009;7:297–306.
- Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 2009;41:138–44.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods 2001;25:402–8.
- Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like signature in poorly differentiated aggressive tumors. Nat Genetics 2008;40:499–507.
- Resar LMS. The high-mobility group A1 gene: transforming inflammatory signals into cancer. Cancer Res 2010;70:436–9.
- Rho YS, Lim YC, Park IS, Kim JH, Ahn HY, Cho SJ, et al. High mobility group HMGA1 protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol 2007;127: 76–81.
- Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat 2009;41:138–44.
- Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkilä S, Vaheri A, et al. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 2008;39:1737–43.
- Froeling FE, Mirza TA, Feakins RM, Seedhar A, Elia G, Hart IR, et al. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, β-catenin, and Ezrin expression in tumor cells. Am J Pathol 2009;175:636–48.